title: [Recommendations for the measurement of blood 25-OH vitamin D].
abstract: The 25-hydroxyvitamin D (25OHD) serum concentration should not be measured to everybody but recommendations for this measurement in several clinical situations are available from numerous guidelines and expert positions. It can be proposed to measure 25OHD in diseases where a target range of 25OHD concentrations associated with better outcomes is defined with a sufficient level of evidence, and when this target concentration is difficult to reach without previous measurement (or may be exceeded in case of too large doses are provided). Many National and International Medical Societies recommend to measure 25OHD at least in any situation of « bone fragility » (defined by a low bone mineral density and/or a low energy fracture), in malabsorptions, in chronic kidney disease, in any « phosphocalcic pathology, in patients with clinical signs of profound vitamin D deficiency or excess, and, more generally in any biological exploration of calcium/phosphorus metabolism that includes the measurement of PTH. Although these recommandations may seem discordant with the recent French restriction in the reimbursment of 25OHD measurement, they may still be reimbursed.
authors.affiliation: Service des explorations fonctionnelles, Hôpital Necker-Enfants malades, Paris AP-HP, France.
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Souberbielle
authors.affiliation: Service de néphrologie pédiatrique, Hôpital Robert Debré, Paris, AP-HP, France.
authors.forename: Georges
authors.initials: G
authors.lastname: Deschenes
authors.affiliation: Service de néphrologie-dialyse-nutrition, Centre hospitalier Lyon-Sud, Hospices civils de Lyon, Pierre Bénite, France.
authors.forename: Denis
authors.initials: D
authors.lastname: Fouque
authors.affiliation: Service d'endocrinologie, Hôpital Cochin, Paris, AP-HP, France.
authors.forename: Lionel
authors.initials: L
authors.lastname: Groussin
authors.affiliation: Service de rhumatologie, CHU de Rennes, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Guggenbuhl
authors.affiliation: Centre de rein artificiel de Tassin, Sainte-Foy-lès-Lyon, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Jean
authors.affiliation: Service d'endocrinologie pédiatrique et Centre de référence des maladies rares du métabolisme du calcium et du phosphore, Hôpital du Kremlin-Bicêtre, Le Kremlin-Bicêtre, AP-HP, France.
authors.forename: Agnès
authors.initials: A
authors.lastname: Linglart
authors.affiliation: Service de rhumatologie, CHU de Saint-Étienne, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Thomas
mesh_terms: D001774:Blood Chemical Analysis / Q000592:standards*; D006801:Humans; D008286:Malabsorption Syndromes / Q000097:blood / Q000150:complications; D010015:Osteolysis, Essential / Q000097:blood / Q000150:complications; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000150:complications; D066027:Transplant Recipients; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000032:analysis / Q000097:blood; D014808:Vitamin D Deficiency / Q000097:blood / Q000175:diagnosis*
chemical_list: D014807:Vitamin D; C104450:25-hydroxyvitamin D
keywords: 25-hydroxyvitamin D assay; Haute autorité de santé; clinical biology; vitamin D